Lv4
432 积分 2021-08-10 加入
CFT1946 Is an Orally Available Brain-Penetrant BRAFV600-Mutant Degrader That Overcomes BRAF Inhibitor Resistance
17天前
已完结
Phase I study of procaspase activating compound-1 (PAC-1) in the treatment of advanced malignancies
19天前
已完结
Structural mechanism of cGAS inhibition by the nucleosome
2个月前
已完结
The molecular basis of tight nuclear tethering and inactivation of cGAS
2个月前
已完结
A cGAS-mediated mechanism in naked mole-rats potentiates DNA repair and delays aging
2个月前
已完结
Even kinase-inactive BRAF is oncogenic
2个月前
已完结
Cadonilimab plus platinum-based chemotherapy ± bevacizumab for persistent, recurrent, or metastatic cervical cancer: Subgroup analyses of COMPASSION-16
3个月前
已关闭
Early T Cell Infiltration Correlates with Anti-CTLA4 Treatment Response in Murine Cancer Models
3个月前
已完结
Immune Microenvironment Differences Between Squamous and Non-squamous Non–small-cell Lung Cancer and Their Influence on the Prognosis
3个月前
已完结
Molecular mechanisms of resistance to BRAF and MEK inhibitors in BRAFV600E non–small cell lung cancer
4个月前
已完结
皖公网安备34019202002308
